Posted by Michael Wonder on 20 Dec 2016
Tonix Pharmaceuticals’ PTSD Phase 3 ready drug candidate, TNX-102 SL, granted breakthrough therapy designation by the FDA
19 December 2016 - Responding to AtEase study results in military-related PTSD population, FDA agrees to work closely with Tonix to develop and review TNX-102 SL for PTSD as efficiently as possible.
Tonix Pharmaceuticals announced today that the U.S. FDA has granted breakthrough therapy designation to TNX-102 SL for the treatment of post-traumatic stress disorder.
